TELESIS BIO INC (TBIO)

Company Profile

Telesis Bio, Inc. engages in the provision of automated multi-omic and synthetic biology solutions. The company is headquartered in San Diego, California and currently employs 219 full-time employees. The company went IPO on 2021-06-18. The firm's synthetic biology solution addresses the bottlenecks across the multi-step process of building deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA), as well as the limitations of solutions that prevent the building of virtually error-free DNA and mRNA at a useable scale. Its on-market and planned solutions include BioXp 3250 system, BioXp 9600 system, BioXp DBC, BioXp portal, BioXp De Novo kits, BioXp Select kits, BioXp Next Generation Sequencing kits, BioXp DBC kits, Benchtop reagents and Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS). BioXp 3250 system is a push-button, walkaway, end-to-end automated workstation that offers endpoint-ready synthetic DNA in as few as 8 hours and mRNA in less than 24 hours. BioXp DBC is engaged in delivering on-demand enzymatic DNA synthesis with design-to-endpoint-ready synthetic RNA in as few as 24 hours.

Company Info

TELESIS BIO INC

10431 Wateridge Circle, Suite 150

San Diego CALIFORNIA 02421

P: 18582284115

CEO: Ronald C. Renaud Jr.

Employees: 219

Website: https://telesisbio.com/